Cavinon Forte 10mg Gedeon medicine treats cerebral blood circulation disorders (2 blisters x 15 tablets)

Vinpocetine protects neuron cells: The drug regulates the harmful effects of cell reactions caused by stimulating amine acids. Na+ and Ca2+ inhibitors depend on voltage as well as NMDA and AMPA receptors. The drug increases the effect of protecting the nerve cells of adenosine.

Vinpocetine stimulates metabolism in the brain: The drug increases the acquisition and consumption of glucose and oxygen in the brain tissue; Increasing tolerance with oxygen deficiency of brain cells, increasing glucose transportation of the brain's only energy source through the brain barrier, the direction of glucose metabolism to the aerobic cycle is more favorable in terms of energy; Selective inhibition of CGMP-GHOSPHODIesterase (PDE) depends on Ca2+-Calmodulin, increasing the Camp and CGMP levels in the brain.

Increases ATP and AMP/AMP levels, increases the flow of norepinephrine and serotonin of the brain, stimulates the noradrenergic system upwards; The drug has an antioxidant effect. The results of the above effects help Vinpocetine have the effect of protecting the brain.

Vinpocetine significantly improves the microcirculation of the brain circulation: Platelet inhibitors; reduce the increase in pathological blood viscosity; Increase the deformation of red blood cells and inhibit the acquisition of adenosine of red blood cells, increase oxygen transport into the brain tissue by reducing oxygen affinity to red blood cells.

Vinpocetine increases the brain circulation selectively: The drug increases the heart of the heart pumped to the brain; Reducing brain -resistant resistance without affecting the parameters of the whole body (blood pressure, cardiac supply, heart rate, total peripheral resistance); Does not cause blood appropriation. Moreover, during the treatment period, the drug also increases blood supply to the brain area (but not necrotic) is low (inversely acting with blood appropriation).

Pharmacokinetics

absorption

Vinpocetine is quickly absorbed. Absolute oral bioavailability is 7%. Plasma peak concentration reaches 1 hour after drinking. The main absorption position lies on the upper part of the gastrointestinal tract. The drug is not metabolized when passing through the intestinal wall.

Distribution

In studies conducted on rats using Vinpocetine radioactive isotopes, the highest concentration of radioactive concentration in the liver and the digestive tract. The highest drug concentration in the tissue is measured at 2-4 hours after drinking. Radioactive concentration measured in the brain is not higher than in the blood.

In humans, the ratio of cohesion to plasma protein is 66%. The distribution volume is 246.7 ± 88.5 liters, which shows significant tissue cohesion. The clearance value of Vinpocetine (66.7 l/hour) exceeds the liver's plasma value (50 l/hour) showing the liver metabolism.

Metabolism

The main metabolites of Vinpocetine are ApovinCaminic acid (AVA), accounting for about 25 - 30% when used for humans. After drinking, the area under the curve of AVA is twice as large as when using intravenously indicates that AVA is formed after the first metabolism of Vinpocetine. Other metabolites are identified as hydroxy - vinpocetine, hydroxy - ava, dihydroxy - ava - glycinate and their complexes with glucuronide and/or sulfate. In the research species, the amount of Vinpocetine is excreted into the urine in the form of constant only a few percent of the dose.

Elimination

Using oral with a repeated dose of 5mg or 10mg Vinpocetine shows linear dynamics; Stable plasma concentration is 1.2 ± 0.27 ng/ml and 2.1 ± 0.33 ng/ml, according to the corresponding appropriate. In humans, the sale time is 4.83 ± 1.29 hours. In studies performed with radioactive compounds, it is found that the drug is excreted mainly through urine and feces at the ratio of 60/40.

In dogs and rats, most of the radioactivity is found from bile origin but has not confirmed the main role of the intestinal circulation. ApovinCaminic acid is excreted by the kidneys by a simple filtration process in the glomerular, the sale time depends on the dose and the drug.

An important and superior feature of Vinpocetine is that it does not need to adjust the dose when used for people with liver or kidneys because the drug is not accumulated.

Changes of pharmacokinetic properties under special conditions (age, disease accompanying): Vinpocetine is mainly used for the elderly, which is the object of the dynamic of the drug has many changes (reducing absorption, difference in distribution and metabolism, reducing excretion), so it is necessary to perform pharmacokinetic studies on this age group, especially when taking long -term drugs.

The results that the dynamics of the drug on the elderly are not significantly different from young people. In case of liver/kidney dysfunction, the usual dose may be used because Vinpocetine is not accumulated, so it can also take long -term drugs.

Most of the unwanted effects are light and go away on their own. If any of the above side effects becomes serious, or if you find any other side effects not mentioned above, you need to notify the doctor or pharmacist.

You need to notify the doctor if you are suffering from any disease (especially heart failure, there are changes on the electrocardiogram).

Be cautious when using

should measure the electrocardiogram in the event of a long QT syndrome or when used simultaneously with another drug that extends the QT range.

The ability to drive and operate machinery

There is no data on the effect of the drug on the ability to drive and operate machinery.

The unwanted effect of the drug can most affect the ability to drive or operate machinery is: headache, dizziness, dizziness, chicken sleep, abnormal heart rate, mental mental reaction, agitation and restlessness. These effects sometimes or rarely occur. Patients experience these unwanted effects when using Vinpocetine should consult a doctor.

Pregnancy

Contraindicated to use Cavinton Forte during pregnancy.

Lactation period

Contraindicated use of Cavinon Forte during breastfeeding.

Drug interaction

When taking Vinpocetine with beta blockers (chloranolol, pinkolol), Clopamide , glibenclamide, digoxin , acenocoumarol or hydrochlorothiazide do not experience drug interactions. In rare cases, there is a mild hypotension effect when sharing Vinpocetine with Alpha - Methyldopa, so it is necessary to check blood pressure regularly when used in combination with these two drugs.

Although clinical data does not show interactions, it is necessary to be cautious when using a combination of Vinpocetine with drugs on the central nervous system, anticoagulic drugs and arrhythmia.